Aspen Pharmacare Long Term Debt 2017-2025 | APNHY

Aspen Pharmacare long term debt from 2017 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Aspen Pharmacare Annual Long Term Debt
(Millions of US $)
2025 $1,736
2024 $1,345
2023 $1,206
2022 $696
2021 $17
2020 $2,320
2019 $2,800
2018 $3,649
2017 $2,124
2016 $2,269
2015
Aspen Pharmacare Quarterly Long Term Debt
(Millions of US $)
2025-06-30 $1,736
2024-06-30 $1,345
2023-12-31 $1,309
2023-06-30 $1,206
2022-12-31 $1,248
2022-06-30 $696
2021-12-31 $1,294
2021-06-30 $17
2020-12-31 $1,878
2020-06-30 $2,320
2019-06-30 $2,800
2018-12-31 $3,670
2018-06-30 $3,649
2017-12-31 $2,168
2017-06-30 $2,124
2016-12-31 $2,563
2016-06-30 $2,269
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $3.708B $2.388B
Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00